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MSH2 Mutat ion Carr iers Are at Higher Risk of Cancer
Than MLH1 Mutat ion Carr iers : A Study of Heredi tary
Nonpolypos is Colorecta l Cancer Famil ies
By H.F.A. Vasen, A. Stormorken, F.H. Menko, F.M. Nagengast, J.H. Kleibeuker, G. Griffioen, B.G. Taal,
P. Moller, and J.T. Wijnen
Purpose: Hereditary nonpolyposis colorectal cancer
(HNPCC) is an autosomal dominant disease character-
ized by the clustering of colorectal cancer, endometrial
cancer, and various other cancers. The disease is caused
by mutations in DNA-mismatch-repair (MMR) genes, most
frequently in MLH1, MSH2, and MSH6. The aims of the
present study were to compare the risk of developing
colorectal, endometrial, and other cancers between fam-
ilies with the various MMR-gene mutations.
Patients and Methods: Clinical and pathologic data
were collected from 138 families with HNPCC. Mutation
analyses were performed for all families. Survival
analysis was used to calculate the cumulative risk of
developing cancer in the various subsets of relatives.
Results: Mutations were identified in 79 families: 34
in MLH1, 40 in MSH2, and five in MSH6. The lifetime risk
of developing cancer at any site was significantly
higher for MSH2 mutation carriers than for MLH1 mu-
tation carriers (P < .01). The risk of developing colorec-
tal or endometrial cancer was higher in MSH2 mutation
carriers than in MLH1 mutation carriers, but the differ-
ence was not significant (P  .13 and P  .057, respec-
tively). MSH2 mutation carriers were found to have a
significantly higher risk of developing cancer of the
urinary tract (P < .05). The risk of developing cancer of the
ovaries, stomach, and brain was also higher in the MSH2
mutation carriers than in the MLH1 mutation carriers, but
the difference was not statistically significant.
Conclusion: Pending large prospective studies, the
extension of the current surveillance program in MSH2
mutation carriers with the inclusion of the urinary tract
should be considered.
J Clin Oncol 19:4074-4080. © 2001 by American
Society of Clinical Oncology.
HEREDITARY NONPOLYPOSIS colorectal cancer(HNPCC) is an autosomal dominant disease charac-
terized by the development of cancer of the colorectum and
endometrium and, less frequently, cancer of the stomach,
urinary tract, ovaries, small bowel, and brain.1 It is caused
by mutations in DNA-mismatch-repair (MMR) genes, pre-
dominantly in MLH1, MSH2, and MSH6 and rarely in PMS1
and PMS2.2 Most estimates of colon cancer risk are derived
from families collected at HNPCC registries and vary
between 60% and 85%.3,4 A recent study on the cancer risk
in mutation carriers identified in a population-based series
of patients with early-onset colorectal cancer reported a
significantly lower colorectal cancer risk in female mutation
carriers.5 The reported risk of developing endometrial
cancer is approximately 40% to 50%.3-5
It is yet to be resolved whether there is a difference in
cancer risk between carriers of the various MMR-gene
mutations. Knowledge about this possible difference in risk
might be important to assist physicians’ decisions on sur-
veillance programs.
Previous studies showed that there was no difference in
risk of colorectal and endometrial cancer between MSH2
and MLH1 mutation carriers.3 However, Danish investiga-
tors have reported that the risk of endometrial cancer is
significantly lower in families with a specific MLH1 muta-
tion,6 and a recent study by our group suggested that
families with MSH6 mutations seemed to have a higher risk
of developing endometrial cancer than families with MSH2
and MLH1 mutations.7 Regarding the less common extra-
colonic cancers, one study suggested that patients with
MSH2 mutations have a higher relative risk of developing
extracolonic cancers than patients with MLH1 mutations.3
All studies published at the present time on the cancer
risk in HNPCC have been hampered by a relatively small
number of patients. We, therefore, evaluated the lifetime
risk of developing cancer in a large series of families with
identified mutations. The specific aims of the present study
were (1) to compare the cancer risk between families with
MLH1, MSH2, and MSH6 mutations and families with a
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not-yet-identified mutation who meet the Amsterdam crite-
ria, and (2) to discuss the consequences for surveillance.
PATIENTS AND METHODS
HNPCC Registry
The Netherlands HNPCC registry was established in 1987. The
methods used by the registry have been reported previously.8 The aims
of the registry on its establishment were to promote surveillance in
families with HNPCC and to guarantee follow-up examinations.
Families with clustering of colorectal cancer were referred to the
registry from all parts of the Netherlands. Pedigree analysis was
performed by social workers or clinical geneticists. The pedigrees were
traced backward and laterally as far as possible. Most pedigrees contain
information on three generations. The data collected at the registry
included personal and medical data on each affected and unaffected
family member. The information on the cancer diagnosis was verified
by medical or pathologic reports. From January to July 2000, a total of
193 families were registered. The collection of information was
completed in all 193 families. A total of 116 families met the
Amsterdam Criteria I or II, and the other 77 families were suspected
of HNPCC.9 Mutation analysis has been performed in all families.
Also, 58 families suspected of HNPCC known at the Clinical
Genetic Centre Radium Hospital (Oslo, Norway) were investigated
by mutation analysis.
Molecular Genetics Study
The techniques used in the mutation analysis have been reported
previously.10 In short, the general strategy was to amplify by polymer-
ase chain reaction each of the 16 exons of MSH2, the 19 exons of
MLH1 and 10 exons of MSH6 in a single affected member in each
family, and to analyze these products by GC-clamped denaturing
gradient gel electrophoresis (DGGE). To determine the molecular
nature of the variant, exons with an altered pattern of migration on
DGGE were sequenced. When variants were detected, the investiga-
tions were extended, if possible to the rest of the family, to verify the
segregation of the nucleotide change with the disease phenotype.
Southern blot analysis for MSH2, MSH6, and MLH1 was done on all
patients negative in the DGGE screening.10
Risk Analysis
The families were subdivided into families with the various MMR-
gene mutations and families without a mutation who met the Amster-
dam I or II criteria. In all subsets of the families, three groups were
regarded as mutation carriers: those relatives affected with cancer of
the colorectum or endometrium, called putative carriers (which ex-
cluded the colorectal or endometrial cancer patients with a proven
noncarrier status); relatives found to be carrying a mutation; and
relatives who were considered to be obligate carriers because of their
position in the pedigree in relation to relatives with a mutation. The
cumulative risk by age was calculated using Kaplan-Meier survival
analysis methods. Only the cancers verified by medical or pathologic
reports were included in the calculations. The observation time was
from birth until date of diagnosis of cancer, death, or to the end of the
study in July 1, 2000. Differences in survival curves were tested for
statistical significance on the basis of the log-rank test. With respect to
the Norwegian families, only those with an identified mutation were
included in the calculations.
RESULTS
Pathogenic mutations were found in 71 Dutch and eight
Norwegian families: 34 in MLH1, 40 in MSH2, and five in
MSH6. All mutations predicted truncation of the protein-
product. Table 1 shows the number of patients with colo-
rectal cancer, endometrial cancer, and their first-degree
relatives in the families with or without a mutation. The
mean age at diagnosis of colorectal cancer was higher in
carriers of MSH6 mutations (mean age, 50.1 years; range,
26 to 69 years) compared with the age at diagnosis of
colorectal cancer in carriers of MLH1 (mean age, 42.8
years; range, 16 to 81 years) and MSH2 mutations (mean
age, 43.9 years; range, 16 to 90 years).
Table 2 shows the frequency of other cancers observed in
the various categories of families. Substantially more can-
cers were observed in families with an MLH1 or MSH2
mutation compared with families with an MSH6 mutation
and families that met the Amsterdam Criteria without an
identified mutation. We did not observe any difference in
phenotype between families with a null mutation (nonsense
mutation and genomic rearrangements) and those with a
splice site mutation.
The lifetime risk of developing cancer at any site was
significantly higher (P  .01) in MSH2 mutation carriers
than in MLH1 mutation carriers (Fig 1). The cumulative
risk of developing colorectal cancer by age in MLH1 and
MSH2 mutation carriers is shown in Fig 2. The risk of
developing colorectal cancer was higher in MSH2 muta-
tion carriers than in MLH1 mutation carriers (P  .13).
Overall, the risk of developing colorectal cancer in male
mutation carriers was higher than the risk of colorectal
cancer in female mutation carriers, but the difference was
Table 1. Number of Families, Patients With Colorectal and Endometrial Cancer, and Their First-Degree Relatives According to Type of Mutation Detected
Mutated Gene
Amsterdam Families
Without Mutation TotalMLH1 MSH2 MSH6
No. of families 34 40 5 60 139
No. of family members 917 925 107 1,273 3,222
No. of patients with colorectal cancer 137 143 15 209 504
No. of patients with endometrial cancer 26 34 4 16 80
No. of first-degree relatives 754 748 78 1,048 2,638
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only statistically significant for MSH2 mutation carriers
(P  .01) (Fig 3). The cumulative risk by age of
developing endometrial cancer is shown in Fig 4. The
risk of developing endometrial cancer was higher in
MSH2 mutation carriers than in MLH1 mutation carriers
(P  .057).
Table 3 shows the cumulative risk of developing
various cancers by age 70 in the putative mutation
carriers. MSH2 mutation carriers were found to have a
significantly higher risk of developing cancer of urinary
tract (cumulative risk by age 70, 12%; P  .05). The risk
of developing cancer of the stomach, ovary, and brain
was also higher in the MSH2 mutation carriers than in the
MLH1 mutation carriers, but the difference was not
statistically significant. There was no difference in the
risk of developing cancer of the small bowel between the
two groups of mutation carriers. Altogether, 21 cases of
urinary tract cancer were observed in 20 patients from 17
families (of which 15 were in putative gene carriers).
There was one family with three cases of urinary tract
cancer and two families with two cases in each. In the
other families there was one case in each family. In
addition, a total of 24 cases of ovarian cancer were found
in 20 families (of which 13 were in putative gene
carriers). In four families there were two cases, and in the
remaining families there was one case per family.
Figure 1. Cumulative risk of developing any cancer by age in putative carriers of mutations in MLH1 and MSH2.
Table 2. Number of Other Cancers in Patients With Colorectal and/or Endometrial Cancer and Their First-Degree Relatives According to Type of MMR
Gene Mutation
Type of Mutation
MLH1 MSH2
MSH6
No.
Amsterdam Families Without Mutation
No.
Mean Age
(years)
Range
(years) No.
Mean Age
(years)
Range
(years) No.
Mean Age
(years)
Range
(years)
No. of families 34 40 5 59
Site of cancer
Stomach 6 53 39-74 15 51 23-82 0 8 68 36-77
Urinary tract 4 63 52-72 14* 56 40-72 0 3 50 37-70
Small bowel 9 50 25-67 7 51 31-69 0 3 54 39-65
Ovary 6 51 35-75 13 45 37-58 0 5 43 19-57
Brain 3 45 21-78 10 41 2-73 0 3 56 36-69
*One patient had two primary urinary tract cancers.
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DISCUSSION
In the present study, we compared the incidence of cancer
between HNPCC families with MLH1, MSH2, and MSH6
mutations and those without a known mutation who met the
Amsterdam Criteria I or II. We found a significantly
increased overall risk for developing cancer in MSH2
mutation carriers compared with carriers of MLH1 muta-
tions. In addition, in MSH2 mutation carriers there was a
significantly higher risk for cancer of the urinary tract (renal
pelvis and ureter) than was the case in MLH1 mutation
carriers. Also, compared with the risk in MLH1 mutation
carriers, the risk of endometrial, ovarian, stomach, and brain
cancer was greater in MSH2 mutation carriers. However,
this difference was not statistically significant.
There was some evidence for clustering of urinary tract
and ovarian cancer in some families. This phenomenon was
also described by Watson and Lynch.11 Possible explana-
tions for this variation in expression among families are the
presence of modifying genes or the influence of environ-
mental factors.
The results of our study might have been biased in
different ways. First of all, the criteria for referral to the
National HNPCC registry were familial clustering of colo-
rectal cancer. Therefore, the ascertainment of the families
might have led to overestimation of the risk of developing
colorectal cancer. However, we don’t expect that the esti-
mated risk of extracolonic cancers and the observed differ-
ences in risk of developing colorectal cancer between the
various groups of mutation carriers were biased by the way
of ascertainment of the families. Secondly, the outcome
of the present study might be influenced by the fact that
only patients who survived were available for mutation
analysis, which led to overrepresentation of tumor types
with a favorable prognosis, such as tumors of the
endometrium and colorectum, and underrepresentation of
tumors with a less favorable prognosis, such as tumors of
the brain and stomach.
Recently, Aarnio et al12 assessed the cancer risk in a large
series of Finnish HNPCC families. Although the results of
the two studies cannot properly be compared, as the cancers
in the Finnish families mainly resulted from MLH1 muta-
tions (47 of the 50 families), there were several conspicuous
differences between them. The reported risk of cancer of the
stomach was substantially higher in the Finnish families
than the risk of these cancers in the Dutch MLH1 mutation
families. In addition, patients with small bowel cancer were
not observed in the Finnish families. The same environmen-
tal factors that are responsible for the higher incidence of
stomach cancer in the general population of Finland com-
pared with the Dutch population may be responsible for the
Figure 2. Cumulative risk of developing colorectal cancer by age in putative carriers of mutations in MLH1 and MSH2.
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differences in incidence between the Dutch and Finnish
MLH1 families. Similar differences have been observed
between Dutch and Korean HNPCC families.13
An intriguing question is why MSH2 mutations are
associated with a higher risk of developing cancer than
MLH1 mutations. The MSH2 protein forms with other mutS
homologues two different mutS protein complexes (MSH2/
MSH6 and MSH2/MSH3) that recognize mispaired bases in
DNA. The MLH1 protein forms with PMS2 a protein
complex that interacts with the mutS protein complex bound
to the mispaired DNA. After binding of these complexes,
excision of the mispaired DNA occurs, followed by DNA
resynthesis.14 In this process both MSH2 and MLH1 pro-
teins play a critical role, and mutations in either genes result
in a complete loss of function. However, a difference
between MLH1 and MSH2 is the role that MSH2 plays in
the control of the homologous recombination of two iden-
tical DNA-strands. If the DNA-strands differ more than 1%,
the MSH2 protein prevents recombination.15 Moreover,
MSH2 seems also to be involved in some pathways of
transcription-coupled repair. This diversity in function
might be responsible for the variation in cancer risk.
The clinical phenotype of families with MSH6 mutations
is still unknown. The first families reported in the literature
were characterized by a late onset of colorectal cancer.16,17
Also, in the present study, the mean age at diagnosis of
colorectal cancer was higher than the age at diagnosis in
families with MLH1 and MSH2 mutations. Recent analysis of
Figure 3. Cumulative risk of developing colorectal cancer by age and sex in putative carriers of mutations in MLH1 and MSH2.
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families with MSH6 mutations revealed a remarkably high
incidence of endometrial cancer.7,18 The reported series even
included families exclusively with endometrial cancer. The
observation of predominantly colorectal cancer in the families
with MSH6 mutations reported in the present series might be
attributed to the fact that the main criteria for referral of
families to the HNPCC Registry was familial clustering of
colorectal cancer. More studies—preferably studies that use
less strict criteria for the selection of families for mutation
analysis18—are needed to provide reliable estimates of cancer
risk in MSH6-associated families.
In our series, we found that the colorectal cancer risk was
higher in male mutation carriers than in female mutation
carriers. This is in parallel with the higher risk of developing
colorectal cancer in males compared with females in the
general population in the Netherlands. A sex difference in
colorectal cancer risk in carriers of mismatch repair gene
mutations was also reported by other investigators.5,12,19
Figure 4. Cumulative risk of developing endometrial cancer by age in putative carriers of mutations in MLH1 and MSH2.
Table 3. Cumulative Risk (%) of Developing Cancer by Age in Carriers of MLH1 or MSH2 Mutations
Age (years)
MLH1 MSH2
40 50 60 70 95% CI 40 50 60 70 95% CI
Stomach* — 0.4 2.1 2.1 0-4.7 0.7 1.2 4.3 4.3 0.5-8.1
Urinary tract† — — — 1.3 0-3.9 0.4 1.5 5.4 12 3.5-20
Small bowel‡ — 0.7 4.0 7.2 1.5-12.9 0.8 1.2 4.5 4.5 0.5-8.5
Ovary§ 0.6 2.3 3.4 3.4 0-6.8 1.7 6.4 10.4 10.4 3.2-17.6
Brain — — — — 1.2 1.2 1.2 1.2 0-2.6
Abbreviation: CI, confidence interval.
*Stomach: MLH1 v MSH2: P  .13
†Urinary tract: MLH1 v MSH2: P  .05
‡Small bowel: MLH1 v MSH2: P  .8
§Ovarian cancer: MLH1 v MSH2: P  .11
Brain tumor: MLH1 v MSH2: P  .06
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According to the guidelines proposed by the International
Group on HNPCC, surveillance of the colorectum and
endometrium (including the ovaries) is recommended for all
mutation carriers, and surveillance of other sites (eg, the
urinary tract and stomach) for mutation carriers from
families that include such types of cancers. In this study,
MSH2 mutation carriers have a significantly increased risk
of developing cancer of the urinary tract. An extended
surveillance program, including surveillance of the urinary
tract, should, therefore, be considered in MSH2 mutation
carriers, pending the outcome of large prospective studies.
The recommended protocol of screening for urinary tract
cancer includes cytologic examination of the urine and
sonography starting at age 30 to 35 years at 1- to 2-year
intervals. However, the sensitivity and specificity of these
tests are yet unknown.20 The protocol of screening of the
endometrium and ovaries includes annual transvaginal
sonography and estimation of CA-125 starting at age 30 to
35 years. Prophylactic oophorectomy might be considered
for women older than 40 years with a complete family.
Because also the value of surveillance of the endometrium
and ovaries is unknown, periodic examination should ide-
ally be performed in the setting of a prospective study. In
the follow-up of mutation carriers, it is important to realize
that the family members may develop cancer at sites that are
not included in the surveillance program. Therefore, clini-
cians managing HNPCC patients should always be alert
when the patient exhibits unusual symptoms.
In conclusion, our study indicates that there are substantial
differences in cancer risk between MLH1 and MSH2 mutation
carriers. On the basis of these results, a more extended
screening program might be considered for MSH2 mutation
carriers. Because there is some evidence that other factors,
such as environmental/life style factors, and modifier genes
play a role in the carcinogenesis, not only the type of the
mutated MMR gene but also the phenotype of the disease in
the family should be taken into account in the decision as to
which surveillance protocol should be recommended.
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